Modern immunosuppression drug regimens have produced excellent short-term survival after liver transplantation but it is generally accepted that the side effects of these medications remain a significant contributing factor for less satisfactory long term outcomes. The liver has unique tolerogenic properties as evidenced by the higher rates of operational tolerance seen in liver transplant recipients compared to other solid organ transplants, and therefore, liver transplantation offers an attractive setting in which to study tolerizing therapies. CD4 +
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Modern immunosuppression drug regimens have produced excellent short-term survival after liver transplantation but it is generally accepted that the side effects of these medications remain a significant contributing factor for less satisfactory long term outcomes. The liver has unique tolerogenic properties as evidenced by the higher rates of operational tolerance seen in liver transplant recipients compared to other solid organ transplants, and therefore, liver transplantation offers an attractive setting in which to study tolerizing therapies. CD4 +
CD25
+ FOXP3 + regulatory T cells (Tregs) are crucial for maintenance of self-tolerance and prevention of autoimmune disease and are therefore an appealing potential candidate for use as a tolerizing cell therapy. In this review, we summarize the evidence from drug withdrawal trials of spontaneous operational tolerance in liver transplantation, the unique immunology of the hepatic microenvironment, the evidence for the use of CD4
+ regulatory T cells as a tolerance inducing therapy in liver transplantation and the challenges in producing clinical grade Treg cell products.
Introduction
The liver has long been recognized to hold unique tolerogenic properties, and consequently, clinical liver transplantation has been an attractive setting in which to study transplantation immunology and more recently tolerance inducing strategies in humans.
A number of regulatory immune cell populations are under investigation as potential immunotherapies, but in this review, we will focus on CD4 + CD25 + FOXP3
+ regulatory T-cell (Treg) therapy and provide a brief introduction to the early evidence for tolerance in liver transplantation, the evidence for the role of Tregs in transplantation tolerance and the clinical trials, which have shown proof of principle for the efficacy of Treg therapy in this setting.
Immunosuppression and side effects
Short-term survival rates following the first liver transplant in 1963 progressively improved in the following decades through advances in surgical techniques, and a further leap was observed with the introduction of calcineurin inhibitor (CNI) immunosuppression in the early 1980s, leading to the 1-year survival rates of 80-85% that are routinely seen in transplant centres around the world today [1] . However, over the next 3 decades, it has become evident that the improvement in shortterm survival has not translated into medium/long-term survival and information obtained from a UK data set of 2702 adult liver transplant recipients found these patients lost on average 7 life years compared to an equivalent non-transplant population [2] . In a study of 299 patients analysing deaths following liver transplantation in those recipients surviving more than 3 years, 58% of late deaths were due to non-hepatic causes with the majority attributed to malignancies and cardiovascular disease [3] . Over the longer term, chronic renal failure is also a significant cause of morbidity and mortality in this population, with rates of severe renal dysfunction occurring in up to 18.1% of those recipients surviving more than 13 years [4] . The fact that nonhepatic causes of mortality predominate in recipients more than 3 years post-transplant has led to the general acceptance that CNI's and other immunosuppressive drugs significantly contribute to this mortality and has steered focus to the investigation of novel immunosuppression minimization strategies, in particular those potentially leading to the complete withdrawal of immunosuppression [3, 5, 6] .
Spontaneous operational tolerance and immunosuppression withdrawal trials
Operational tolerance is defined as stable graft function in a recipient off immunosuppressant drugs and in whom no clinically significant detrimental immune response or immune defects are detected [7] [8] [9] [10] . In the absence of robust biomarkers of tolerance, the only reliable way of confirming the establishment of tolerance is by intentionally withdrawing immunosuppression. When exploring the use of tolerizing cell therapies in liver transplantation, it is important to consider the occurrence and prevalence of spontaneous operational tolerance, which has long been recognized in this setting and occurs with greater frequency than in the context of any other solid organ transplant. Therefore, it is important to establish the factors favouring spontaneous operational tolerance when utilizing liver transplant recipient populations, in which this phenomenon may occur frequently and potentially be a confounding factor for end points of therapeutic success. Since early anecdotal reports of spontaneous tolerance in non-compliant patients and the subsequent retrospective analyses and single-centre trials [11] [12] [13] [14] [15] [16] [17] [18] [19] , several prospective multicentre immunosuppression withdrawals trials have helped to establish the rates of tolerance, in both the paediatric and adult liver transplant populations. Furthermore, they have clarified the patient and clinical factors that determine the likelihood of spontaneous tolerance. The first prospective multicentre trials of immunosuppression withdrawal in the paediatric population by Feng et al. in 2012 and in adult liver transplant recipients by Benitez et al. in 2013 reported rates of operational tolerance of 60% and 41%, respectively, in patients more than 3 years (adult) or 4 years (paediatric) post-transplantation, without a history of autoimmune liver disease, and not more than minimal inflammatory infiltrates in their liver biopsies [20, 21] . Both these studies therefore utilized a highly selected group of liver transplant recipients and in those medically supervised drug withdrawal trials with less selective inclusion criteria, lower rates of spontaneous operational tolerance of between 5.6% and 38% were observed [11, 12, [14] [15] [16] [17] [18] [19] 22, 23] . These trials identified that the time elapsed from transplantation was the most significant factor associated with the frequency of spontaneous tolerance. Patients underwent weaning according to strict protocols, and in this setting when rejection did occur, it was usually easily treated, and the overall strategy was considered safe. While these prospective drug withdrawal trials were not designed or powered to show a reduction in the long term effects of IS, longer term follow-up data derived from previous single-centre studies, suggest that the minimization of IS exposure in tolerant patients could reduce deterioration in renal function and metabolic parameters [5, 24, 25] .
Unique characteristics of the hepatic immunological microenvironment
Most notably, clinical human liver transplantation is distinguished from other solid organ transplants in that it does not require preconditioning induction immunosuppression regimens in the face of a positive crossmatch, does not require HLA matching and allows the safe application of lower blood levels of immunosuppression than both those employed in other solid organ transplant recipients and those recommended by pharmaceutical manufacturers [26, 27] .
The liver is continuously presented with a large volume of foreign antigens via the portal venous system and selectively reacts to blood-borne pathogens, while preventing excessive immunological activation against an array of nonpathogenic antigens derived from the translocation of food and bacterial degradation products [28, 29] . A prime example is the response to chronic exposure to bacteria-derived lipopolysaccharide (LPS) recognized by Toll-like receptors, in which the normal proinflammatory response through activation of intracellular signalling cascades leads to anti-inflammatory responses and the production of inhibitory cytokines, for example 31] .
Following allogeneic organ transplantation, proinflammatory responses are triggered by the recognizing of donor MHC molecules by recipient T cells and animal models demonstrate this arises whether the organ is eventually rejected or tolerance occurs. However, in the case of tolerance, the inflammation is short-lived through the inactivation/deletion of graft infiltrating lymphocytes [32] [33] [34] . In addition, the liver can act as a secondary lymphoid organ, activating and retaining CD4 + and CD8 + na€ ıve T cells following antigen presentation by an array of conventional and nonconventional APCs including dendritic cells, macrophages, B lymphocytes, stellate cells (HSC), hepatocytes and liver sinusoidal endothelial cells [35] [36] [37] [38] [39] . In particular, when hepatocytes act as APCs, the result is transient clonal expansion of naive CD8 + cells but due to a lack of costimulation this is followed by apoptosis [39] [40] [41] [42] . In addition, in vivo murine models show an increase in the frequency of Tregs following the adoptive transfer of HSC suggesting that APCs drive differentiation to an immunosuppressive Treg phenotype [43] .
The description of a thymus-derived suppressor CD4 + T-cell population by Hall et al. in 1990 was further characterized in 1995 by Sakaguchi et al. [44, 45] by the expression of the IL2 receptor a (CD25) that was critical for self-tolerance and avoidance of the development of autoimmune disease. Further characterization proved the FOXP3 transcription factor was required for the generation, maintenance and function of Tregs and has subsequently become the most widely used, albeit not entirely specific, marker for this lymphocyte subpopulation [46, 47] .
Tregs are capable of suppressing CD4 + and CD8 + Tcell immune responses through a number of mechanisms including inhibitory cytokine production, for example IL-10 and TGF b, cytolysis, induction of effector T-cell apoptosis and inhibition of APCs [48] . The significant role for Tregs in preventing rejection and inducing tolerance has been demonstrated in rodent models of liver transplantation [49] [50] [51] .
Several studies in human liver transplantation have described an increased frequency of Tregs in the peripheral blood of operational tolerance recipients [52, 53] . Dynamic analysis during weaning of immunosuppression showed a significant increase in the relative frequency and absolute Tregs numbers in patients who proved tolerant compared to those that rejected [16] . These observations need to be interpreted with caution given the confounding effects of CNIs, which decrease the number of circulating Tregs and are not always adequately accounted for. Furthermore, Tregs are known to migrate to sites of inflammation, which results in their accumulation in the liver during episodes of liver allograft rejection (where their frequency as compared to that of effector T cells tends to be higher than in noninflamed grafts), with a corresponding reduction in their peripheral blood numbers [16, [54] [55] [56] . In this regard, data derived from sequential liver biopsies performed in patients undergoing IS withdrawal has been more informative, as it indicates that tolerance is associated with a transient intragraft inflammatory response that includes enrichment in Tregs [16, 54, 55] , which closely resembles what has been described in experimental animal models.
Proinflammatory immune responses are important for protection from viral and bacterial pathogens and there is evidence to suggest that the immunosuppressive effects of Tregs could be potentially detrimental in acute and chronic infections. Mechanisms include limiting CD8 + viral destruction, CD8 + T-cell proliferation and recruitment of virus-specific CD8 + T cells, therefore creating an immunological environment favouring persistent viral infection [57] [58] [59] [60] [61] .
In the context of bacterial infections, Tregs have also been shown in humans to expand in line with effector T cells in mycobacterial tuberculosis and in mouse models, Treg depletion led to a lower bacterial burden, and co-transfer of Tregs led to an increase in bacterial burden in the lungs [62] [63] [64] [65] .
The unquestionable pivotal role of Tregs in the establishment of tolerance in animal models as described above, the circumstantial evidence indicating that Tregs are likely to be involved in the regulation of intrahepatic inflammatory responses in human liver transplant recipients, and the fact that it is possible to generate large numbers of human Tregs both ex vivo and in vivo, makes them ideal candidates for use as a potential tolerizing cell therapy. Tregs therefore offer the promise of targeted allograft tolerance in contrast to the indiscriminate inhibition of alloimmune responses seen with current immunosuppression medications.
Ex vivo expanded regulatory T cells
In the context of allogeneic solid organ transplantation, it is recognized that the excess of alloreactive effector T cells overwhelms the relatively smaller number of functional regulatory T cells in favouring rejection and graft destruction [66] . In animal models, it is possible to suppress alloreactive effector T-cell responses and to induce tolerance by providing an excess of Tregs. Thus, utilizing Tregs as a strategy to induce tolerance relies on shifting the balance in favour of Tregs, either through diminishing the number or function of effector T cells or increasing the relative frequency or function of Tregs or both [67] [68] [69] . For this review, we will focus on the following therapeutic approaches to achieve a favourable effector T-cell/Treg ratio in humans: 1 Delivery of ex vivo expanded Treg cellular therapy 2 The pharmacological in vivo induction/expansion of Tregs.
In animal transplant models, a ratio of Tregs to effector T cells of 1:2 has been shown to be required for prevention of rejection [67, [70] [71] [72] . It has been estimated that based on an 70-kg human, collection of the maximum number of 8 9 10 9 lymphocytes by a single leukapheresis procedure would only provide 0.2 9 10 9 Tregs. Even employing therapeutic lymphodepletion therapy such as the use of Thymoglobulin, which has less effect on depleting Tregs than effector T cells [73, 74] , it has been estimated that infusion of this number of Tregs would only provide a 3.7% increase to 16.7% of CD4 + T cells [75] . Thus, ex vivo expansion of purified Tregs is required to achieve the predicted 49-79 9 10 9 cells to reach a therapeutic 33-55% of the CD4 + population [75] . These estimations are however made on the use of polyclonal Tregs and up to 10 times less may be required if alloantigen-reactive Tregs, which are more potent than polyclonal Tregs are used [76] [77] [78] .
The production of clinical grade Tregs is challenging and will be reviewed below. Tregs can be reliably identified by a panel of cell surface markers with cells expressing CD4, high levels of CD25 (the high affinity IL-2 receptor a chain of the IL-2 receptor) and low levels of the CD127 (IL-7 receptor). However, utilizing FOXP3, the most accurate phenotypic marker of Tregs is limited as it is an intracellular protein and therefore cannot be used for the purification of intact cells. Furthermore, transplant recipients and patients with chronic liver disease tend to be lymphopenic and may have reduced Treg numbers and/or function, which may compromise cell isolation and expansion. Despite this, protocols for the successful production of clinical grade polyclonal and antigen-specific Tregs have been reported [79, 80] .
Preclinical animal models demonstrated the infusion of ex vivo expanded recipient Tregs can produce indefinite acceptance of heart allografts in murine models and the delay in islet allograft rejection in a humanized murine model [77, 81] . Early trials in human subjects have largely utilized the setting of bone marrow transplantation and type 1 diabetes, which have provided limited data in terms of efficacy but reassuringly a good safety profile [82] [83] [84] [85] .
The tolerance inducing efficacy of a regulatory T-cell therapy has recently been shown in living donor liver transplantation utilizing an ex vivo generated Tregenriched cell product in 10 consecutive adult patients [86] . In this Japanese study, seven of the recipients were male with a median age of 56 years old and with a median meld score of 15. The indications for transplant were NASH, HCC (NASH, HBV), alcohol, HCV, PBC and PSC. All patients underwent splenectomy at the time of transplantation and received methylprednisolone, mycophenolate and CNI immunosuppression. Methylprednisolone and mycophenolate were weaned and stopped within the first postoperative month. A single dose of cyclophosphamide (40 mg/kg) was given on day 5, and a single infusion of the cell product was then given on day 13 post-transplantation. Donor and recipient lymphocytes were procured by leukapheresis prior to transplantation. Recipient lymphocytes and splenocytes were co-cultured with irradiated donor lymphocytes in the presence of costimulatory blockade (anti-CD80/CD86) to enrich for anergic and/or regulatory donor-specific T cells. The T-cell-enriched cell product was a mixture of CD4 + , CD8 + lymphocytes accounting for 58.6% and 16.9% of infused cells, respectively, with a varying composition of monocytes, NK cells, B cells, myeloid DCs, plasmacytoid DCs and granulocytes. The number of CD4 + CD25 + FOXP3 + T cells infused varied between patients ranging from 0.23 9 10 6 /kg to 6.37 9 10 6 /kg and with a mean of 3.39 9 10 6 /kg (AE2.12 SD) [86] . Seven patients with nonimmunological liver diseases successfully achieved uneventful weaning and completed cessation of IS. At the time of the publication of the study, these patients had been off immunosuppression between 16 and 33 months. Significantly, the doses of cells infused were much lower than those estimated to be required on the basis of animal studies. This study therefore provides a proof of principle of the efficacy of Treg therapy in liver transplantation. Furthermore, it confirms previous observations made in the setting of drug withdrawal trials indicating that those patients with a history of immune-mediated liver disease aetiology are very unlikely to develop allograft tolerance.
Treg therapy trials in progress
Several clinical trials are currently in progress around the world utilizing a number of Treg therapies in liver transplantation (Table 1 ). An ex vivo expanded polyclonal regulatory T-cell therapy is being utilized in the ThRIL trial at King's College Hospital, UK [clinical trials.gov NCT02166177], the DeLTA and ARTEMIS trials at University of California, San Francisco, USA, are using donor-alloantigen-reactive regulatory T cells (darTregs) [NCT02188719] NCT02474199, and a further collection of trial designs at Nanjing Medical University, China, is utilizing donor-antigen-specific Tregs in patients at early and late time points following liver transplantation [NCT01624077] .
Clinical Grade (GMP) Treg production challenges and future perspectives Many clinical trials in solid organ transplantation have utilized a living donation transplant setting as this provides access to prospective identification of the donor and access to donor tissue ahead of a planned procedure. As such the cellular product can be manufactured ahead of the transplant operation and infusion of the cell product in the early post-transplant period. However, the overwhelming majority of liver transplant programmes across the world utilize allografts from deceased donors, which only provides donor identification and therefore access to donor tissue a few hours prior to the procedure. In order for future ex vivo expanded cell therapies to have universal and wide spread application in liver transplantation, cell production processes will need to obviate the requirement for access to donor tissue or utilize immediate peri-transplant procurement of both donor and recipient cellular starting materials, which will inevitably lead to infusion of the cell product at relatively later time points.
The current (2017) manufacturing procedures for Treg Investigational Medicinal Products are resource intensive. Expansion times can take up to 6 weeks in clean-room facilities and often require batch segregation when the patient from which the starting materials were procured is serologically positive for viral markers. The challenge is made bigger because there are so few licensed sites with the capability to make Tregs under GMP conditions. This will be a major factor in the adoption of Tregs therapy as part of standard care for transplant recipients should it prove to be safe and beneficial. These issues could be addressed with enhanced expansion procedures. Current static culture systems could be replaced with bioreactors using, for example, rocking motion to reduce expansion times and increase scale, and thus shortening clean-room occupancy times.
Clean-room occupancy also comes with a cost; the most costly part of Treg production is the raw materials. Upstream processing, selection of target cells using magnetic or fluorescent antibodies, uses highly specialized reagents and sterile tubing sets. This, coupled with cell culture reagents and cytokines required, typically amounts to a current cost of approximately £30,000 per batch. Wider adoption of Treg therapy could reduce these costs with the economies of scale in supply of consumables, but it remains the responsibility of the manufacturers of cell therapies to address cost-of-goods so that the financial burden on healthcare providers is minimized. This issue is particularly important for Treg production, because unlike other cell therapies there is no economy possible through the allogeneic-production route; each autologous batch is unique, and the demands are for scale-out, not the more easily cost-efficient scale-up. There is a drive to develop Treg production procedures that will yield antigen-specific suppressive cells, in order to minimize off-target immune suppression. These procedures are not well defined currently, and there may be a need to introduce antigen presenting cells (APCs) into a Treg-culture system that will be both effective and cause no contamination of the product downstream. One approach could be to render the functional APCs unable to divide with irradiation. Alternatively, downstream purification procedures might be adopted, like antibody-mediated methods used in upstream processing; either method is likely to be costly.
The purity of Treg products has been difficult to control, due partly to contaminating cells selected in upstream processes. Magnetic selection has benefits of scale and throughput, but is crudely binary, and positive selection can occur just once. If the upstream process reduces CD8 cells and selects cells that are CD25-immunoreactive, the resulting culture can start with a low Treg purity. We have used selective culture conditions (e.g. media containing rapamycin) to suppress the growth of contaminating cells, but this has not always been sufficient. A better approach in the future will be to obtain highly pure cells at the outset, and this will require scalable fluorescently activated cell sorting (FACS) in aseptic closed systems, which is currently under development.
Purity is necessary to exclude contaminating (and potentially counterproductive) cells and to enable potency. Methods of determining potency of a Treg product require a better understanding of Treg function. There are numerous modes of action (inhibitory cytokines, cytolysis, metabolic disruption and APC targeting) [87] , and not all can be tested. This presents the quality-control analyst with a challenge, as the choice of potency assay might not predict efficacy. And relying on cell-based assays, like suppression of T-effector growth, can yield unpredictable results; the future will require simpler methods for potency assays.
In short, manufacturers of Tregs cell therapy products will supply future markets by shortening expansion times, reducing costs-of-goods, delivering antigen-specificity, enhancing cell purity and controlling potency.
In vivo Treg expansion
Calcineurin inhibitors (CNIs) are the mainstay of immunosuppression in liver transplantation and have proven very effective in reducing the activity of Th1-and Th17-mediated tissue allograft damage. The CNIs impede the activity of effector T-cell function and IL-2 transcription by inhibiting the T-cell receptor translocation of nuclear factor of activated T cells (NFAT) into the nucleus [88] [89] [90] . Tregs depend on IL-2 signalling for their development, survival and function and respond to very low levels of IL-2 due to the high expression of the IL-2 Receptor a chain (CD25). It is therefore recognized that CNI therapy also has a undesirable effect on Tregs which are dependent on IL-2 and NFAT to efficiently express FOXP3 and curb the transcription of proinflammatory genes [91] [92] [93] . As a result, transplanted patients on CNI therapy exhibit a lower number of Tregs [88, 94] .
Several clinical trials have demonstrated clinical efficacy of low dose IL-2 in patients with steroid refractory chronic graft versus host disease and HCV related vasculitis by preferentially expanding Tregs [95, 96] . The use of IL-2 resulted in an up to 8 times expansion of Tregs without a significant increase in conventional T cells. This provides the promise of expanding the in vivo Treg pool without the requirement for expensive and large-scale production facilities required to produce clinical grade Tregs.
The potential beneficial effects of regulatory T cells are to be investigated in the setting of liver transplantation in the LITE Trial (NCT02949492) at King's College London, which is due to start recruiting early 2017.
Conclusion
Clinical immunosuppression withdrawal trials demonstrate the spontaneous achievement of allograft tolerance in the setting of liver transplantation due to the unique hepatic immunological environment. However, spontaneous operational tolerance occurs late after transplantation, and in order for the potential benefits of immunosuppression withdrawal to be realized, tolerance induction strategies will be required to promote tolerance at earlier time points. Regulatory T cells play a crucial role in tolerance and the first trial utilizing an ex vivo expanded regulatory T-cell therapy in the setting of liver transplantation has shown therapeutic promise. 
